Icatibant Viatris

Icatibant, the active ingredient in Icatibant Viatris, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous injection for subcutaneous use. It selectively blocks bradykinin‑mediated vasodilation and vascular permeability, providing rapid relief of swelling during acute hereditary angioedema attacks in diagnosed patients.

GNH USA supplies Icatibant Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Icatibant is used to treat hereditary angioedema by targeting the bradykinin pathway.

- Hereditary angioedema type I: provides rapid reduction of swelling during acute attacks. - Hereditary angioedema type II: alleviates symptoms of sudden edema in affected individuals. - Hereditary angioedema with normal C1‑INH: offers prompt relief of attack‑related swelling.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient increase in local tissue volume. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe angioedema: unexpected swelling of face, lips, or airway. - Hypotension: marked drop in blood pressure requiring medical attention. - Thrombocytopenia: low platelet count observed in laboratory tests. - Infection at injection site: signs of cellulitis or abscess formation. - Severe headache or migraine: persistent, intense head pain.

Before initiating therapy, clinicians should consider several safety measures.

- Confirm diagnosis: ensure the patient has a confirmed hereditary angioedema diagnosis. - Monitor hypersensitivity: watch for signs of allergic reaction at the injection site. - Avoid in known hypersensitivity: do not administer to patients with documented allergy to icatibant or its excipients. - Pregnancy: safety not established; weigh potential benefits against risks. - Breastfeeding: unknown excretion; consider alternatives. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or hemodynamics.

Major Interactions (Avoid): - ACE inhibitors: concurrent use may increase bradykinin levels and worsen angioedema. - Neprilysin inhibitors: may elevate bradykinin and reduce efficacy of icatibant.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may increase frequency of HAE attacks, monitor patient response. - NSAIDs: can exacerbate swelling in some patients, observe for increased symptoms. - Other B2 receptor antagonists: concurrent use may lead to additive effects, adjust therapy as needed.